Tags

Type your tag names separated by a space and hit enter

Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Clin Nutr. 2016 06; 35(3):578-86.CN

Abstract

BACKGROUND

& aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH.

METHODS

Patients received three capsules daily, each containing 0.315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment.

RESULTS

At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega-3 PUFAs, plasma ALA and EPA levels increased (p ≤ 0.05). However in the placebo group, we also observed increased EPA and DHA (p ≤ 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01).

CONCLUSIONS

In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology. (ID 01992809).

Links

Publisher Full Text

Aggregator Full Text

Authors+Show Affiliations

University of São Paulo School of Medicine, Department of Gastroenterology, Clinical Division of Clinical Gastroenterology and Hepatology (LIM-07), São Paulo, Brazil.

University of São Paulo School of Medicine, Department of Gastroenterology, Clinical Division of Clinical Gastroenterology and Hepatology (LIM-07), São Paulo, Brazil.

Ferreira Alves VA

University of São Paulo School of Medicine, Department of Pathology (LIM-14), São Paulo, Brazil.

University of São Paulo School of Medicine, Department of Gastroenterology, Clinical Division of Clinical Gastroenterology and Hepatology (LIM-07), São Paulo, Brazil.

University of São Paulo School of Medicine, Department of Gastroenterology, Surgery Division (LIM-35), São Paulo, Brazil.

University of São Paulo School of Medicine, Department of Gastroenterology, Surgery Division (LIM-35), São Paulo, Brazil.

University of São Paulo School of Medicine, Department of Gastroenterology, Clinical Division of Clinical Gastroenterology and Hepatology (LIM-07), São Paulo, Brazil.

University of São Paulo School of Medicine, Department of Emergency (LIM-51), Sao Paulo, Brazil.

University of São Paulo School of Medicine, Department of Gastroenterology, Clinical Division of Clinical Gastroenterology and Hepatology (LIM-07), São Paulo, Brazil.

University of São Paulo School of Medicine, Department of Gastroenterology, Surgery Division (LIM-35), São Paulo, Brazil. Electronic address: dan@ganep.com.br.

Pub Type(s)

Comparative Study

Journal Article

Randomized Controlled Trial

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26047766

Citation

Nogueira, Monize Aydar, et al. "Omega-3 Polyunsaturated Fatty Acids in Treating Non-alcoholic Steatohepatitis: a Randomized, Double-blind, Placebo-controlled Trial." Clinical Nutrition (Edinburgh, Scotland), vol. 35, no. 3, 2016, pp. 578-86.

Nogueira MA, Oliveira CP, Ferreira Alves VA, et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2016;35(3):578-86.

Nogueira, M. A., Oliveira, C. P., Ferreira Alves, V. A., Stefano, J. T., Rodrigues, L. S., Torrinhas, R. S., Cogliati, B., Barbeiro, H., Carrilho, F. J., & Waitzberg, D. L. (2016). Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition (Edinburgh, Scotland), 35(3), 578-86. https://doi.org/10.1016/j.clnu.2015.05.001

Nogueira MA, et al. Omega-3 Polyunsaturated Fatty Acids in Treating Non-alcoholic Steatohepatitis: a Randomized, Double-blind, Placebo-controlled Trial. Clin Nutr. 2016;35(3):578-86. PubMed PMID: 26047766.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. AU - Nogueira,Monize Aydar, AU - Oliveira,Claudia Pinto, AU - Ferreira Alves,Venâncio Avancini, AU - Stefano,José Tadeu, AU - Rodrigues,Lívia Samara Dos Reis, AU - Torrinhas,Raquel Susana, AU - Cogliati,Bruno, AU - Barbeiro,Hermes, AU - Carrilho,Flair José, AU - Waitzberg,Dan Linetzky, Y1 - 2015/05/21/ PY - 2014/09/23/received PY - 2015/03/27/revised PY - 2015/05/08/accepted PY - 2015/6/7/entrez PY - 2015/6/7/pubmed PY - 2018/1/18/medline KW - Alpha-linolenic acid KW - Docosahexaenoic acid KW - Eicosapentaenoic acid KW - Fish oil KW - Flaxseed oil KW - Nonalcoholic steatohepatitis SP - 578 EP - 86 JF - Clinical nutrition (Edinburgh, Scotland) JO - Clin Nutr VL - 35 IS - 3 N2 - BACKGROUND: & aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH. METHODS: Patients received three capsules daily, each containing 0.315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment. RESULTS: At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega-3 PUFAs, plasma ALA and EPA levels increased (p ≤ 0.05). However in the placebo group, we also observed increased EPA and DHA (p ≤ 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01). CONCLUSIONS: In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology. (ID 01992809). SN - 1532-1983 UR - https://www.unboundmedicine.com/medline/citation/26047766/Omega_3_polyunsaturated_fatty_acids_in_treating_non_alcoholic_steatohepatitis:_A_randomized_double_blind_placebo_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(15)00131-4 DB - PRIME DP - Unbound Medicine ER -